.Attribute Medicine, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA study, after an average follow-up of 11 months, individuals with metastatic intestinal cysts that obtained biomarker-matched treatments based on flowing growth DNA profiling showed a higher clinical perk than those obtaining unequaled therapy.